AIkido Pharma Setting Up to Be Major Player in
The Booming $176BIL Anti-Cancer Therapeutics Sector
With Their Latest Blockbuster News!
Dear Fellow Trader,
Immediately turn your attention to AIkido Pharma Inc. (AIKI)
AIkido Pharma Is An Artificial Intelligence-Cancer Fighting-Biotech
Company Like You’ve Never Seen Before.
The Company has several bullish catalysts in the pipeline, and is on the verge of disrupting a $176BIL Anti-Cancer Therapeutics Market, with latest Blockbuster News AIKI secures early investment in Next Generation Radiotherapy Company Convergent Therapeutics currently in Human Phase 2 Trials for Treatment of Prostate Cancer.
This acquisition, instantly positions AIkido Pharma as a significant player in rapidly expanding $176 Billion Anti-Cancer Therapeutics Market!
Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.
Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy ("PRRT") that targets the prostate-specific membrane antigen ("PSMA") present on prostate cancer cells.
The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.
The key component of Convergent's PRRT prostate cancer therapy is its proprietary drug, CONV 01-a, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter.
The function of CONV 01-a is unique in that it not only binds specifically to the PSMA receptor on prostate cancer cells, but also stimulates the internalization of the receptor along with itself and its powerful radioactive payload directly into tumor cells.
Convergent is presently conducting two sets of human clinical trials using CONV 01-a as a single agent treatment for prostate cancer.
The first is a Phase 1a/2a Single Ascending Dose Trial of CONV 01-a and the results are expected to be released in Q2 2021.
In August of 2020, Convergent began a second Phase 1b/2a trial to test the efficacy of multiple ascending doses of CONV 01-a.
If FDA approved, CONV 01-a would be the first antibody drug approved to direct a radioisotope into prostate cancer cells, and the first drug approved for the use of 225Ac in cancer treatment.
Another company is currently studying PSMA I&T-ß, containing 177Lu, and has just completed a phase 3 trial in prostate cancer. Separately, Novartis (NYSE: NVS) is pursuing FDA approval for another 177Lu-small molecule drug for prostate cancer treatment, designated 177Lu-PSMA-617, which also binds PSMA. Novartis has recently completed a phase 3 registration trial for treatment of metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer. Like PSMA I&T-ß, Novartis's 177Lu-PSMA-617 may also be a promising candidate for use with CONV 01-a in the proprietary dual PRRT therapy.
Aikido's CEO, stated, "This is by far the most advanced technology in which the Company has participated. The first of the human trials is wrapping up, with data to be reported shortly, and with the remaining trials either underway or scheduled to begin imminently. Participation in this advanced work represents a major and potentially transformative step for the Company and we are honored to be a part of it. I optimistically anticipate the first of the results to be released next quarter. We will update our shareholders as soon as the data is released."
AIkido Pharma Setting Up To Be A Major Player In The $176 Billion
Anti-Cancer Therapeutics Market That Is Exploding Exponentially!
Another Catalyst Is Convergent Therapeutics Experienced
First in Class Operational Team.
The operational team are some of the brightest people in the world!
Once you wrap your head around who the operational team and founder is, I can assure you that you too will see we could potentially have another big breakout gainer on our hands.
Philip Kantoff, MD CEO - Convergent Therapeutics
Memorial Sloan Kettering Cancer Center (MSK)
Chairman, Department of Medicine, 2015-present
Grew faculty at MSK’s Department of Medicine by >200 (currently ~484 total) through recruitment of national and international clinical and research leaders in oncology
Increased the annual research funding of the Department of Medicine to over $300 million dollars. An increase of 78% since starting in 2015
Created and pushed forward research programs that have produced dozens of cancer related FDA drug approvals
Steered the department through the COVID-19 crisis
Neil Bander, MD CSO / Founder - Convergent Therapeutics
Weill Cornell Medicine
Bernard and Josephine Chaus Professor of Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine
His team has the world’s largest experience in antibody discovery and clinical development in urological oncology.
Developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients.
Pioneered the clinical validation of PSMA and PSMA-Targeted Therapeutics (Radionuclides and Antibody-Drug Conjugates).
John Cullity, MD MBA CFO / CBO
Managing Director at BioSynergy Partners, a life science advisory spun out of Torreya New York where he was CBO.
Provides strategic advisory on M&A, partnering and financing to life-science companies worldwide.
Chairman Race Oncology (RAC.ASX). Director of several life sciences start-ups.
Oncology BD team leader and Head of Strategic Pricing at Sanofi, Health Economist at Schering Plough, Consultant at A.T. Kearney.
Board certified internist: Royal College of Physicians, UK. Wharton MBA.
Upgraded Bullish - FDCT is Off to A Strong Start!
Are You Watching? Looking Very Strong as Volume Surges!
So far, FDCT is breaking out to the upside fast hitting a high of $.57 yesterday up 23% from previous sessions close.
There has been a massive shift into Bitcoin and Cryptocurrency, prices have climbed after stock trading app Robinhood stepped in to restrict users from GameStop and other stocks that have surged in recent days.
We are in the midst of another Crypto Frenzy and companies like FDCT have the potential to make serious moves this week.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have FDCT pulled up on your trading screen.
Sincerely,
Editor In Chief, OTCtipReporter Team
